While progress has been made in the fight against healthcare-associated infections (HAIs), they are still among the leading threats to patient safety. HAIs affect one out of every 25 hospital patients at any one time. Over a million HAIs occur across the U.S. healthcare system every year, leading to the loss of tens of thousands of lives and adding billions of dollars to healthcare costs.1 By combining early and accurate detection of HAIs with appropriate infection control interventions and patient treatment, we can prevent transmission, improve patient management and reduce the financial burden on healthcare systems.
BD’s deep history in microbiology—from plated media to molecular diagnostics—demonstrates our unique strength in helping hospitals manage the spread of infections. BD offers a comprehensive suite of molecular solutions designed to detect healthcare-associated infections on the BD MAX™ System. The BD MAX System delivers automated extraction, amplification and detection of the most common HAIs, with up to 24 patient results in just over 2 hours.
A test for patients suspected of having CDI through the detection of the Clostridium difficile toxin B gene (tcdB) from liquid or soft stool.2 Learn More>>
A screening test for nasal carriage of MRSA aiding in transmission prevention and infection control.3 Learn More>>
A pre-surgical screening test for nasal carriage of Staphylococcus aureus or MRSA aiding in transmission prevention and infection control.4 Learn More>>